Allogene Therapeutics (ALLO) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed DBV Technologies S.A. (DBVT) over the past year, gaining 5.9% versus a loss of 31.4%. Over five years, DBVT leads with a -7.8% price change compared with -91.3% for ALLO. DBV Technologies S.A. is the larger company by market cap ($614.0 million vs $494.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | DBVT |
|---|---|---|
| Share price | $1.43 | $9.77 |
| Market cap | $494.05M | $614.03M |
| 1-day change | -2.05% | -2.10% |
| YTD return | +4.38% | -49.03% |
| 1-year return | +5.93% | -31.39% |
| 5-year return | -91.32% | -7.83% |
| EPS (TTM) | $-0.66 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $26.19 |
| 52-week low | $1.04 | $9.64 |
| Distance from 52-week high | -67.94% | -62.69% |
| Average volume | 5.78M | 328.30K |
| Shares outstanding | 345.49M | 62.85M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed DBVT by 37.3 percentage points over the past year.
ALLO vs DBVT FAQ
Which is bigger, Allogene Therapeutics or DBV Technologies S.A.?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $614.03M compared with $494.05M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or DBVT?
ALLO returned +5.93% over the past 12 months, compared with -31.39% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.